RHYTHM PHARMACEUTICALS, INC. - COM (RYTM)

Historical Holders from Q4 2017 to Q4 2025

Type / Class
Equity / COM
Symbol
RYTM on Nasdaq
Shares outstanding
66,399,673
Price per share
$107.04
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares as of 30 Sep 2025
70,889,646
Holdings value
$7,159,045,368
% of all portfolios
0.01%
Share change
+4,233,519
Value change
+$449,473,155
Average buys %
+0%
Average sells %
-0%
Number of holders
262
Price from insider filings
$111.00
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of RHYTHM PHARMACEUTICALS, INC. - COM (RYTM) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BAKER BROS. ADVISORS LP 8.9% $263,130,477 5,604,483 Baker Bros. Advisors LP 31 Mar 2025
RA CAPITAL MANAGEMENT, L.P. 8.7% $542,844,252 5,561,359 RA Capital Management, L.P. 30 Jun 2025
VANGUARD GROUP INC 7.5% $504,589,163 4,996,427 The Vanguard Group 30 Sep 2025
PERCEPTIVE ADVISORS LLC 6.8% $207,680,555 4,423,441 Perceptive Advisors LLC 31 Mar 2025
BlackRock, Inc. 6.9% $204,922,665 4,364,700 BlackRock, Inc. 31 Mar 2025
PRIMECAP MANAGEMENT CO/CA/ 6.4% -16% $430,506,130 -$62,126,826 4,262,859 -13% PRIMECAP MANAGEMENT CO/CA/ 30 Sep 2025
GOLDMAN SACHS GROUP INC 3% $85,398,854 1,818,932 THE GOLDMAN SACHS GROUP, INC. 31 Dec 2024
As of 30 Sep 2025, RHYTHM PHARMACEUTICALS, INC. - COM (RYTM) has 262 institutional shareholders filing 13F forms. They hold 70,889,646 shares .

Top 25 institutional shareholders own 82% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
BlackRock, Inc. 9.5% 6,302,215 +0.55% 0.01% $636,460,694
RA CAPITAL MANAGEMENT, L.P. 8.6% 5,681,359 +2.2% 7.1% $573,760,445
BAKER BROS. ADVISORS LP 8.4% 5,604,483 0% 4.1% $565,996,738
VANGUARD GROUP INC 7.5% 4,996,427 +39% 0.01% $504,589,163
PRIMECAP MANAGEMENT CO/CA/ 6.4% 4,262,859 -13% 0.33% $430,506,130
NEA Management Company, LLC 4.4% 2,909,956 0% 16% $293,876,456
PERCEPTIVE ADVISORS LLC 3.7% 2,438,969 +0.85% 7.2% $246,311,479
FMR LLC 3.2% 2,145,183 +9.8% 0.01% $216,642,009
STATE STREET CORP 3.1% 2,028,651 +6.3% 0.01% $204,873,464
GOLDMAN SACHS GROUP INC 2.9% 1,893,663 +9.2% 0.03% $191,241,026
FEDERATED HERMES, INC. 2.6% 1,727,885 +2.5% 0.31% $174,499,106
PRICE T ROWE ASSOCIATES INC /MD/ 2.1% 1,399,897 +4.4% 0.02% $141,377,000
Driehaus Capital Management LLC 2.1% 1,383,775 +9% 1% $139,747,437
GEODE CAPITAL MANAGEMENT, LLC 2.1% 1,362,829 +3.9% 0.01% $137,654,057
Polar Capital Holdings Plc 1.9% 1,244,932 -0.47% 0.61% $125,725,683
JPMORGAN CHASE & CO 1.8% 1,188,069 +52% 0.01% $119,983,088
JANUS HENDERSON GROUP PLC 1.7% 1,160,887 -18% 0.05% $117,237,978
WESTFIELD CAPITAL MANAGEMENT CO LP 1.6% 1,069,004 -34% 0.45% $107,958,714
ALKEON CAPITAL MANAGEMENT LLC 1.5% 1,017,700 0% 0.46% $102,777,523
ALLIANCEBERNSTEIN L.P. 1.5% 979,682 +1494% 0.03% $98,938,085
Checkpoint Capital L.P. 1.2% 763,707 -28% 26% $77,126,770
Rock Springs Capital Management LP 1.1% 717,102 -17% 4.2% $72,420,131
Pictet Asset Management Holding SA 1% 683,017 +64% 0.07% $68,952,135
Capital Research Global Investors 0.9% 598,247 0.01% $60,416,965
Woodline Partners LP 0.87% 580,183 +13% 0.28% $58,592,681

Institutional Holders of RHYTHM PHARMACEUTICALS, INC. - COM (RYTM) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q4 17,828 $1,908,552 -$23,455,203 $107.04 6
2025 Q3 70,889,646 $7,159,045,368 +$449,473,155 $100.99 262
2025 Q2 66,543,505 $4,204,958,379 +$136,584,157 $63.19 225
2025 Q1 64,595,384 $3,424,911,068 -$18,829,114 $52.97 226
2024 Q4 64,917,500 $3,634,216,597 -$154,967,284 $55.98 202
2024 Q3 67,633,760 $3,542,730,734 -$89,041,484 $52.39 178
2024 Q2 69,303,085 $2,846,274,465 +$55,480,400 $41.06 165
2024 Q1 67,970,508 $2,943,611,078 +$57,195,827 $43.33 169
2023 Q4 80,273 $3,690,150 -$183,237 $45.97 3
2023 Q3 68,143,293 $1,562,080,097 +$52,384,052 $22.92 143
2023 Q2 66,212,640 $1,092,126,780 +$94,872,230 $16.49 116
2023 Q1 56,555,459 $1,008,940,021 -$50,412,022 $17.84 124
2022 Q4 62,315,169 $1,814,633,448 +$85,319,986 $29.12 115
2022 Q3 59,485,390 $1,445,333,394 +$425,331,067 $24.50 96
2022 Q2 44,285,623 $183,787,988 -$10,542,625 $4.15 77
2022 Q1 48,387,008 $557,366,977 +$5,264,240 $11.52 101
2021 Q4 48,382,013 $482,849,595 -$577,340 $9.98 89
2021 Q3 47,716,597 $623,208,206 +$5,067,526 $13.06 92
2021 Q2 47,332,279 $902,596,313 -$4,691,524 $19.58 100
2021 Q1 47,577,204 $1,011,968,096 +$147,674,681 $21.27 121
2020 Q4 40,465,979 $1,199,975,923 +$38,678,744 $29.73 113
2020 Q3 39,249,591 $850,611,960 -$43,715,003 $21.67 114
2020 Q2 41,219,166 $919,171,883 +$11,797,880 $22.30 87
2020 Q1 40,800,199 $620,976,603 -$33,703,535 $15.22 79
2019 Q4 39,986,197 $918,077,101 +$204,869,654 $22.96 88
2019 Q3 31,230,077 $674,245,813 +$64,824,294 $21.59 83
2019 Q2 28,187,960 $620,070,946 +$8,597,860 $22.00 81
2019 Q1 30,856,102 $845,856,903 -$21,943,308 $27.41 84
2018 Q4 31,656,058 $850,970,460 +$12,832,028 $26.88 72
2018 Q3 30,339,252 $884,997,537 -$10,279,567 $29.17 74
2018 Q2 31,030,594 $966,429,352 +$213,480,320 $31.26 84
2018 Q1 20,379,585 $405,555,382 -$5,859,479 $19.90 52
2017 Q4 21,606,212 $627,880,658 +$506,806,498 $29.06 64